Table 1 SEER-Medicare study population (1993–2005): soft tissue sarcoma patients (n = 3,480) and non-cancer controls (n = 3,480)
| Â | Cancer | Non-cancer | ||
|---|---|---|---|---|
n | % | N | % | |
Age in years | ||||
 65–69 | 475 | 13.7 | 549 | 15.8 |
 70–74 | 825 | 23.7 | 836 | 24.0 |
 75–79 | 880 | 25.3 | 853 | 24.5 |
 80–84 | 744 | 21.4 | 715 | 20.6 |
 85+ | 556 | 16.0 | 527 | 15.1 |
Race | ||||
 Black | 300 | 8.6 | 301 | 8.7 |
 White | 2,967 | 85.3 | 2,945 | 84.6 |
 Other/unknown race | 213 | 6.1 | 234 | 6.7 |
Sex | ||||
 Female | 1,843 | 53.0 | 1,972 | 56.7 |
 Male | 1,637 | 47.0 | 1,508 | 43.3 |
STS subtype | ||||
 Sarcoma NOS | 1,422 | 40.9 | na | na |
 GIST | 845 | 24.3 | na | na |
 Leiomyosarcoma | 264 | 7.6 | na | na |
 Maligant fibrous histiocytoma | 224 | 6.4 | na | na |
 Angiosarcoma | 184 | 5.3 | na | na |
 Liposaroma | 136 | 3.9 | na | na |
 Nerve sheath tumor | 118 | 3.4 | na | na |
 Fibrosarcoma | 64 | 1.8 | na | na |
 Synovial Sarcoma | 49 | 1.4 | na | na |
 Osteosarcoma | 44 | 1.3 | na | na |
 Rhabdomyosarcoma | 25 | 0.7 | na | na |
 Chondrosarcoma | 25 | 0.7 | na | na |
 Dermatofibrosaroma | 22 | 0.6 | na | na |
 Ewing sarcoma | 19 | 0.5 | na | na |
 Maligant hemangiopericytoma | 15 | 0.4 | na | na |
 Clear cell sarcoma | <11 | 0.3 | na | na |
 Myxosarcoma | <11 | 0.2 | na | na |
 Alveolar soft part | <11 | 0.1 | na | na |
 Maligant granular cell tumor | <11 | 0.1 | na | na |
 Maligant giant cell tumor | <11 | 0.0 | na | na |
Primary site | ||||
 Connective/subcutaneous tissue | 1,217 | 35.0 | na | na |
 Digestive system | 1,107 | 31.8 | na | na |
 Respiratory system | 279 | 8.0 | na | na |
 Breast | 178 | 7.7 | na | na |
 Other non-epithelial skin | 167 | 5.1 | na | na |
 Female genital system | 160 | 4.8 | na | na |
 Urinary system | 105 | 4.6 | na | na |
 Other and unknown | 267 | 3.0 | na | na |
Stage | ||||
 Unstaged | 482 | 13.9 | na | na |
 Localized | 1,482 | 42.6 | na | na |
 Regional | 800 | 23.0 | na | na |
 Distant | 716 | 20.5 | na | na |